Richard Messmann Joins Apexian as Chief Medical Officer

Xconomy Indiana — 

Apexian Pharmaceuticals has brought on Richard Messmann as the biotech company’s chief medical officer. Before joining Indianapolis-based Apexian, Messmann was chief medical officer of ProNAi Therapeutics in Vancouver, Canada. His 25 years of cancer drug development experience includes stints at Eli Lilly & Co. (NYSE: LLY), Endocyte (NASDAQ: ECYT), Great Lakes Cancer Institute at Michigan State University, and the National Cancer Institute.